1
|
De Bernardi N, Duecker RP, Zielen S, Schubert R, Eickmeier O. Epigenetische Regulation der Resolution der Inflammation bei
Cystischer Fibrose. Klinische Pädiatrie 2022. [DOI: 10.1055/s-0042-1754511] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- N De Bernardi
- Universitätsklinikum Frankfurt, Klinik für Kinder- und
Jugendmedizin, Abteilung für Allergologie, Pneumologie und Cystische
Fibrose, Frankfurt am Main, Germany
| | - RP Duecker
- Universitätsklinikum Frankfurt, Klinik für Kinder- und
Jugendmedizin, Abteilung für Allergologie, Pneumologie und Cystische
Fibrose, Frankfurt am Main, Germany
| | - S Zielen
- Universitätsklinikum Frankfurt, Klinik für Kinder- und
Jugendmedizin, Abteilung für Allergologie, Pneumologie und Cystische
Fibrose, Frankfurt am Main, Germany
| | - R Schubert
- Universitätsklinikum Frankfurt, Klinik für Kinder- und
Jugendmedizin, Abteilung für Allergologie, Pneumologie und Cystische
Fibrose, Frankfurt am Main, Germany
| | - O Eickmeier
- Universitätsklinikum Frankfurt, Klinik für Kinder- und
Jugendmedizin, Abteilung für Allergologie, Pneumologie und Cystische
Fibrose, Frankfurt am Main, Germany
| |
Collapse
|
2
|
Mainz J, Zagoya C, Polte L, Naehrlich L, Sasse L, Eickmeier O, Smaczny C, Barucha A, Bechinger L, Duckstein F, Eschenhagen P, Kurzidim L, Caley L, Peckham D, Schwarz C. WS02.01 Abdominal symptoms significantly decline after 24 weeks of elexacaftor/tezacaftor/ivacaftor treatment: first results obtained with the cystic fibrosis-specific CFAbd-Score in Germany and the UK. J Cyst Fibros 2022. [DOI: 10.1016/s1569-1993(22)00159-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
3
|
Röhmel J, Dörfler F, Koerner-Rettberg C, Brinkmann F, Schlegtendal A, Wetzke M, Helms S, Große-Onnebrink J, Yu Y, Nuesslein T, Wojsyk-Banaszak I, Becker S, Eickmeier O, Sommerburg O, Omran H, Stahl M, Mall M, Rudolf I. ePS5.09 Comparison of the Lung Clearance Index in preschool children with primary ciliary dyskinesia and cystic fibrosis. J Cyst Fibros 2022. [DOI: 10.1016/s1569-1993(22)00327-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
4
|
Gardecki J, Heyen N, Eickmeier O, Bratan T, Schlangen M, Eidt-Koch D, Smaczny C, Rohde G, Wagner T. P248 Patient Science: a new citizen science approach for health and medical research involving people affected by cystic fibrosis. J Cyst Fibros 2021. [DOI: 10.1016/s1569-1993(21)01273-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
5
|
Fussbroich D, Colas RA, Eickmeier O, Trischler J, Jerkic SP, Zimmermann K, Göpel A, Schwenger T, Schaible A, Henrich D, Baer P, Zielen S, Dalli J, Beermann C, Schubert R. A combination of LCPUFA ameliorates airway inflammation in asthmatic mice by promoting pro-resolving effects and reducing adverse effects of EPA. Mucosal Immunol 2020; 13:481-492. [PMID: 31907365 PMCID: PMC7181394 DOI: 10.1038/s41385-019-0245-2] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2018] [Revised: 11/24/2019] [Accepted: 12/02/2019] [Indexed: 02/04/2023]
Abstract
Lipid mediators derived from omega (n)-3 and n-6 long-chain polyunsaturated fatty acids (LCPUFA) play key roles in bronchoconstriction, airway inflammation, and resolution processes in asthma. This study compared the effects of dietary supplementation with either a combination of LCPUFAs or eicosapentaenoic acid (EPA) alone to investigate whether the combination has superior beneficial effects on the outcome of asthmatic mice. Mice were sensitized with house dust mite (HDM) extract, and subsequently supplemented with either a combination of LCPUFAs or EPA alone in a recall asthma model. After the final HDM and LCPUFA administration, airway hyperresponsiveness (AHR), bronchoalveolar lavages, and lung histochemistry were examined. Lipid mediator profiles were determined by liquid chromatography coupled with tandem mass spectrometry (LC-MS-MS). The LCPUFA combination reduced AHR, eosinophilic inflammation, and inflammatory cytokines (IL-5, IFN-γ, and IL-6) in asthmatic mice, whereas EPA enhanced inflammation. The combination of LCPUFAs was more potent in downregulating EPA-derived LTB5 and LTC5 and in supporting DHA-derived RvD1 and RvD4 (2.22-fold and 2.58-fold higher levels) than EPA alone. Ex vivo experiments showed that LTB5 contributes to granulocytes' migration and M1-polarization in monocytes. Consequently, the LCPUFA combination ameliorated airway inflammation by inhibiting adverse effects of EPA and promoting pro-resolving effects supporting the lipid mediator-dependent resolution program.
Collapse
Affiliation(s)
- D. Fussbroich
- grid.430588.2Department of Food Technology, University of Applied Sciences Fulda, Fulda, Germany ,0000 0004 1936 9721grid.7839.5Division for Allergy, Pneumology and Cystic Fibrosis, Department for Children and Adolescence, Goethe-University, Frankfurt/Main, Germany ,0000 0004 1936 9721grid.7839.5Faculty of Biological Sciences, Goethe University Frankfurt/Main, Frankfurt/Main, Germany
| | - R. A. Colas
- 0000 0001 2171 1133grid.4868.2Lipid Mediator Unit, William Harvey Research Institute, Bart’s and the London School of Medicine, Queen Mary University of London, London, UK
| | - O. Eickmeier
- 0000 0004 1936 9721grid.7839.5Division for Allergy, Pneumology and Cystic Fibrosis, Department for Children and Adolescence, Goethe-University, Frankfurt/Main, Germany
| | - J. Trischler
- 0000 0004 1936 9721grid.7839.5Division for Allergy, Pneumology and Cystic Fibrosis, Department for Children and Adolescence, Goethe-University, Frankfurt/Main, Germany
| | - S. P. Jerkic
- 0000 0004 1936 9721grid.7839.5Division for Allergy, Pneumology and Cystic Fibrosis, Department for Children and Adolescence, Goethe-University, Frankfurt/Main, Germany
| | - K. Zimmermann
- grid.430588.2Department of Food Technology, University of Applied Sciences Fulda, Fulda, Germany
| | - A. Göpel
- grid.430588.2Department of Food Technology, University of Applied Sciences Fulda, Fulda, Germany
| | - T. Schwenger
- grid.430588.2Department of Food Technology, University of Applied Sciences Fulda, Fulda, Germany
| | - A. Schaible
- 0000 0004 1936 9721grid.7839.5Department of Trauma, Hand & Reconstructive Surgery, Goethe-University, Frankfurt/Main, Germany
| | - D. Henrich
- 0000 0004 1936 9721grid.7839.5Department of Trauma, Hand & Reconstructive Surgery, Goethe-University, Frankfurt/Main, Germany
| | - P. Baer
- 0000 0004 1936 9721grid.7839.5Division of Nephrology, Department of Internal Medicine III, Goethe-University, Frankfurt/Main, Germany
| | - S. Zielen
- 0000 0004 1936 9721grid.7839.5Division for Allergy, Pneumology and Cystic Fibrosis, Department for Children and Adolescence, Goethe-University, Frankfurt/Main, Germany
| | - J. Dalli
- 0000 0001 2171 1133grid.4868.2Lipid Mediator Unit, William Harvey Research Institute, Bart’s and the London School of Medicine, Queen Mary University of London, London, UK ,0000 0001 2171 1133grid.4868.2Centre for inflammation and Therapeutic Innovation, Queen Mary University of London, London, UK
| | - C. Beermann
- grid.430588.2Department of Food Technology, University of Applied Sciences Fulda, Fulda, Germany
| | - R. Schubert
- 0000 0004 1936 9721grid.7839.5Division for Allergy, Pneumology and Cystic Fibrosis, Department for Children and Adolescence, Goethe-University, Frankfurt/Main, Germany
| |
Collapse
|
6
|
Fussbroich D, Kohnle C, Schwenger T, Driessler C, Dücker RP, Eickmeier O, Gottwald G, Jerkic SP, Zielen S, Kreyenberg H, Beermann C, Chiocchetti AG, Schubert R. A combination of LCPUFAs regulates the expression of miRNA-146a-5p in a murine asthma model and human alveolar cells. Prostaglandins Other Lipid Mediat 2019; 147:106378. [PMID: 31698144 DOI: 10.1016/j.prostaglandins.2019.106378] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2019] [Revised: 08/14/2019] [Accepted: 09/09/2019] [Indexed: 12/20/2022]
Abstract
BACKGROUND LCPUFAs are suggestive of having beneficial effects on inflammatory diseases such as asthma. However, little is known about the modulative capacity of omega-(n)-3 and n-6 LCPUFAs within the epigenetic regulation of inflammatory processes. OBJECTIVE The aim of this study was to investigate whether a specific combined LCPUFA supplementation restores disease-dysregulated miRNA-profiles in asthmatic mice. In addition, we determined the effect of the LCPUFA supplementation on the interaction of the most regulated miRNA expression and oxygenase activity in vitro. METHODS Sequencing of miRNA was performed by NGS from lung tissue of asthmatic and control mice with normal diet, as well as of LCPUFA supplemented asthmatic mice. Network analysis and evaluation of the biological targets of the miRNAs were performed by DIANA- miRPath v.3 webserver software, TargetScanMouse 7.2, and tool String v.10, respectively. Expression of hsa-miRNA-146a-5p and activity of COX-2 and 5-LO in LCPUFA-treated A549 cells were assessed by qPCR and flow cytometry, respectively. RESULTS In total, 62 miRNAs were dysregulated significantly in murine allergic asthma. The LCPUFA combination restored 21 of these dysregulated miRNAs, of which eight (mmu-miR-146a-5p, -30a-3p, -139-5p, -669p-5p, -145a-5p, -669a-5p, -342-3p and -15b-5p) were even normalized compared to the control levels. Interestingly, six of the eight rescued miRNAs are functionally implicated in TGF-β signaling, ECM-receptor interaction and fatty acid biosynthesis. Furthermore, in vitro experiments demonstrated that upregulation of hsa-miRNA-146a-5p is accompanied by a reduction of COX-2 and 5-LO activity. Moreover, transfection experiments revealed that LCPUFAs inhibit 5-LO activity in the presence and absence of anti-miR-146a-5p. CONCLUSION Our results demonstrate the modulative capacity of LCPUFAs on dysregulated miRNA expression in asthma. In addition, we pointed out the high regulative potential of LCPUFAs on 5-LO regulation and provided evidence that miR-146a partly controls the regulation of 5-LO.
Collapse
Affiliation(s)
- D Fussbroich
- Department of Food Technology, University of Applied Sciences, Leipziger Str. 123, Fulda, Germany; Division for Allergy, Pneumology and Cystic Fibrosis, Department for Children and Adolescents, Goethe University, Theodor-Stern-Kai 7, Frankfurt/Main, Germany; Faculty of Biological Sciences, Goethe University Frankfurt/Main, Max-von-Laue-Straße 9, Frankfurt/Main, Germany.
| | - C Kohnle
- Division for Allergy, Pneumology and Cystic Fibrosis, Department for Children and Adolescents, Goethe University, Theodor-Stern-Kai 7, Frankfurt/Main, Germany
| | - T Schwenger
- Department of Food Technology, University of Applied Sciences, Leipziger Str. 123, Fulda, Germany
| | - C Driessler
- Division for Allergy, Pneumology and Cystic Fibrosis, Department for Children and Adolescents, Goethe University, Theodor-Stern-Kai 7, Frankfurt/Main, Germany
| | - R P Dücker
- Division for Allergy, Pneumology and Cystic Fibrosis, Department for Children and Adolescents, Goethe University, Theodor-Stern-Kai 7, Frankfurt/Main, Germany
| | - O Eickmeier
- Division for Allergy, Pneumology and Cystic Fibrosis, Department for Children and Adolescents, Goethe University, Theodor-Stern-Kai 7, Frankfurt/Main, Germany
| | - G Gottwald
- Division for Allergy, Pneumology and Cystic Fibrosis, Department for Children and Adolescents, Goethe University, Theodor-Stern-Kai 7, Frankfurt/Main, Germany
| | - S P Jerkic
- Division for Allergy, Pneumology and Cystic Fibrosis, Department for Children and Adolescents, Goethe University, Theodor-Stern-Kai 7, Frankfurt/Main, Germany
| | - S Zielen
- Division for Allergy, Pneumology and Cystic Fibrosis, Department for Children and Adolescents, Goethe University, Theodor-Stern-Kai 7, Frankfurt/Main, Germany
| | - H Kreyenberg
- Division for Stem Cell Transplantation and Immunology, Department for Children and Adolescents, University Hospital, Goethe University, Theodor-Stern-Kai 7, Frankfurt/Main, Germany
| | - C Beermann
- Department of Food Technology, University of Applied Sciences, Leipziger Str. 123, Fulda, Germany
| | - A G Chiocchetti
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Goethe University, Theodor-Stern-Kai 7, Frankfurt/Main, Germany
| | - R Schubert
- Division for Allergy, Pneumology and Cystic Fibrosis, Department for Children and Adolescents, Goethe University, Theodor-Stern-Kai 7, Frankfurt/Main, Germany
| |
Collapse
|
7
|
Fussbroich D, Zimmermann K, Göpel A, Eickmeier O, Trischler J, Zielen S, Schubert R, Beermann C. A specific combined long-chain polyunsaturated fatty acid supplementation reverses fatty acid profile alterations in a mouse model of chronic asthma. Lipids Health Dis 2019; 18:16. [PMID: 30658644 PMCID: PMC6339374 DOI: 10.1186/s12944-018-0947-6] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2018] [Accepted: 12/17/2018] [Indexed: 12/31/2022] Open
Abstract
Background The immune-modulating potential of long-chain polyunsaturated fatty acids (LCPUFAs) based on their conversion into lipid mediators in inflammatory situations has been proven by several studies. Respecting the immune-modulative role of lipid mediators in bronchoconstriction, airway inflammation and resolution of inflammatory processes, LCPUFAs play an important role in asthma. To design a disease-specific and most beneficial LCPUFA supplementation strategy, it is essential to understand how asthma alters LCPUFA profiles. Therefore, this study characterizes the alterations of LCPUFA profiles induced by allergic asthma. In addition, this study explores whether a simple eicosapentaenoic acid (EPA) alone or a specific combined LCPUFA supplementation could restore imbalanced LCPUFA profiles. Methods Mice were sensitized with a daily dose of 40 μg house dust mite (HDM)-extract in a recall model and fed with either normal diet, EPA or a specific combined (sc)-LCPUFA supplementation containing EPA, docosahexaenoic acid (DHA), γ -linolenic acid (GLA) and stearidonic acid (SDA) for 24 days. After recall with HDM, mice were sacrificed and blood and lung tissue were collected. Fatty acid profiles were determined in plasma, blood cells and lung cells of asthmatic mice by capillary gas-chromatography. Results In lung cells of asthmatic mice, arachidonic acid (AA, p < 0.001) and DHA (p < 0.01) were increased while dihomo-γ-linolenic acid (DGLA, p < 0.05) was decreased. EPA supplementation increased only EPA (p < 0.001) and docosapentaenoic acid (DPA, p < 0.001), but neither DGLA nor DHA in lung cells of asthmatic mice. In contrast, a specific combined dietary supplementation containing n-3 and n-6 LCPUFAs could decrease AA (p < 0.001), increase EPA (p < 0.001), DPA (p < 0.001) and DHA (p < 0.01) and could reverse the lack of DGLA (p < 0.05). Conclusions In summary, allergic asthma alters LCPUFA profiles in blood and lung tissue. In contrast to the EPA supplementation, the distinct combination of n-3 and n-6 LCPUFAs restored the LCPUFA profiles in lung tissue of asthmatic mice completely. Subsequently, sc-LCPUFA supplementation is likely to be highly supportive in limiting and resolving the inflammatory process in asthma. Electronic supplementary material The online version of this article (10.1186/s12944-018-0947-6) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- D Fussbroich
- Department of Food Technology, University of Applied Science Fulda, Leipziger Str. 123, 36039, Fulda, Germany. .,Division for Allergy, Pneumology and Cystic Fibrosis, Department for Children and Adolescence, Goethe University, Theodor-Stern-Kai 7, Frankfurt/Main, Germany. .,Faculty of Biological Sciences, Goethe University, Max-von-Laue-Straße 13, Frankfurt/Main, Germany.
| | - K Zimmermann
- Department of Food Technology, University of Applied Science Fulda, Leipziger Str. 123, 36039, Fulda, Germany
| | - A Göpel
- Department of Food Technology, University of Applied Science Fulda, Leipziger Str. 123, 36039, Fulda, Germany
| | - O Eickmeier
- Division for Allergy, Pneumology and Cystic Fibrosis, Department for Children and Adolescence, Goethe University, Theodor-Stern-Kai 7, Frankfurt/Main, Germany
| | - J Trischler
- Division for Allergy, Pneumology and Cystic Fibrosis, Department for Children and Adolescence, Goethe University, Theodor-Stern-Kai 7, Frankfurt/Main, Germany
| | - S Zielen
- Division for Allergy, Pneumology and Cystic Fibrosis, Department for Children and Adolescence, Goethe University, Theodor-Stern-Kai 7, Frankfurt/Main, Germany
| | - R Schubert
- Division for Allergy, Pneumology and Cystic Fibrosis, Department for Children and Adolescence, Goethe University, Theodor-Stern-Kai 7, Frankfurt/Main, Germany
| | - C Beermann
- Department of Food Technology, University of Applied Science Fulda, Leipziger Str. 123, 36039, Fulda, Germany
| |
Collapse
|
8
|
Schwarz C, Schulte-Hubbert B, Bend J, Abele-Horn M, Baumann I, Bremer W, Brunsmann F, Dieninghoff D, Eickmeier O, Ellemunter H, Fischer R, Grosse-Onnebrink J, Hammermann J, Hebestreit H, Hogardt M, Hügel C, Hug M, Illing S, Jung A, Kahl B, Koitschev A, Mahlberg R, Mainz JG, Mattner F, Mehl A, Möller A, Muche-Borowski C, Nüßlein T, Puderbach M, Renner S, Rietschel E, Ringshausen FC, Schmidt S, Sedlacek L, Sitter H, Smaczny C, Tümmler B, Vonberg R, Wielpütz MO, Wilkens H, Wollschläger B, Zerlik J, Düesberg U, van Koningsbruggen-Rietschel S. [CF Lung Disease - a German S3 Guideline: Module 2: Diagnostics and Treatment in Chronic Infection with Pseudomonas aeruginosa]. Pneumologie 2018; 72:347-392. [PMID: 29758578 DOI: 10.1055/s-0044-100191] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
Abstract
Cystic Fibrosis (CF) is the most common autosomal-recessive genetic disease affecting approximately 8000 people in Germany. The disease is caused by mutations in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene leading to dysfunction of CFTR, a transmembrane chloride channel. This defect causes insufficient hydration of the epithelial lining fluid which leads to chronic inflammation of the airways. Recurrent infections of the airways as well as pulmonary exacerbations aggravate chronic inflammation, lead to pulmonary fibrosis and tissue destruction up to global respiratory insufficiency, which is responsible for the mortality in over 90 % of patients. The main aim of pulmonary treatment in CF is to reduce pulmonary inflammation and chronic infection. Pseudomonas aeruginosa (Pa) is the most relevant pathogen in the course of CF lung disease. Colonization and chronic infection are leading to additional loss of pulmonary function. There are many possibilities to treat Pa-infection. This is a S3-clinical guideline which implements a definition for chronic Pa-infection and demonstrates evidence-based diagnostic methods and medical treatment for Pa-infection in order to give guidance for individual treatment options.
Collapse
Affiliation(s)
- C Schwarz
- Charité - Universitätsmedizin Berlin, Klinik für Pädiatrie mit Schwerpunkt Pneumologie, Immunologie und Intensivmedizin, Christiane Herzog Zentrum, Berlin
| | - B Schulte-Hubbert
- Medizinische Klinik und Poliklinik I, Pneumologie, Universitätsklinikum Dresden
| | - J Bend
- Mukoviszidose Institut, Bonn
| | - M Abele-Horn
- Universität Würzburg, Institut für Hygiene und Mikrobiologie
| | - I Baumann
- Universität Heidelberg, Hals-Nasen-Ohrenklinik, Heidelberg
| | | | - F Brunsmann
- Charité Universitätsmedizin Berlin, Deutschland (Patientenvertreter)
| | - D Dieninghoff
- Kliniken der Stadt Köln, Lungenklinik, Lehrstuhl der Universität Witten Herdecke
| | - O Eickmeier
- Klinikum der Johann Wolfgang Goethe-Universität Frankfurt am Main, Christiane Herzog CF-Zentrum, Frankfurt
| | - H Ellemunter
- Tirolkliniken GmbH, Department für Kinderheilkunde Pädiatrie III, Innsbruck, Österreich
| | - R Fischer
- Zentrum für erwachsene Mukoviszidose-Patienten München-West
| | - J Grosse-Onnebrink
- Universitätsklinikum Münster UKM; Klinik für Kinder- und Jugendmedizin; Allgemeine Pädiatrie Mukoviszidose-Ambulanz, Münster
| | - J Hammermann
- Universitäts-Mukoviszidose-Zentrum "Christiane Herzog", Dresden
| | | | - M Hogardt
- Klinikum der Johann Wolfgang Goethe-Universität Frankfurt am Main, Institut für Medizinische Mikrobiologie und Krankenhaushygiene, Frankfurt
| | - C Hügel
- Klinikum der Johann Wolfgang Goethe-Universität Frankfurt am Main, Zentrum der Inneren Medizin, Frankfurt, Deutschland
| | - M Hug
- Universitätsklinikum Freiburg, Apotheke des Klinikums Freiburg
| | - S Illing
- Olgahospital - Kinderklinik - CF-Zentrum/Jugendliche/Erwachsene Stuttgart
| | - A Jung
- Kinderspital Zürich, Abteilung Pneumologie, Zürich, Schweiz
| | - B Kahl
- Universitätsklinikum Münster UKM, Institut für Medizinische Mikrobiologie, Münster
| | - A Koitschev
- Klinikum Stuttgart - Standort Olgahospital, Klinik für Hals-Nasen-Ohrenkrankheiten, Stuttgart
| | - R Mahlberg
- Klinikum Mutterhaus der Borromäerinnen, Abteilung Innere Medizin, Trier
| | - J G Mainz
- Universitätsklinikum Jena, Mukoviszidosezentrum/Pädiatrische Pneumologie, Jena
| | - F Mattner
- Kliniken der Stadt Köln, Institut für Hygiene, Köln
| | - A Mehl
- Charité - Universitätsmedizin Berlin, Klinik für Pädiatrie mit Schwerpunkt Pneumologie, Immunologie und Intensivmedizin, Christiane Herzog Zentrum, Berlin
| | - A Möller
- Pneumologie und CF Ambulanz der Universitäts-Kinderklinik Zürich, Schweiz
| | - C Muche-Borowski
- Philipps-Universität Marburg, AWMF-Institut für Medizinisches Wissensmanagement, Marburg und Universitätsklinikum Hamburg-Eppendorf, Institut und Poliklinik für Allgemeinmedizin, Hamburg
| | - T Nüßlein
- Gemeinschaftsklinikum Mittelrhein, Klinik für Kinder- und Jugendmedizin Koblenz und Mayen
| | - M Puderbach
- Hufeland Klinikum, Abteilung für Diagnostische und Interventionelle Radiologie, Bad Langensalza
| | - S Renner
- Allgemeines Universitätskrankenhaus, Klinik für Kinder- und Jugendheilkunde, CF Ambulanz, Wien, Österreich
| | - E Rietschel
- Mukoviszidose-Zentrum Köln, Klinik und Poliklinik für Kinder- und Jugendmedizin, Universität zu Köln
| | - F C Ringshausen
- Medizinische Hochschule Hannover, Klinik für Pneumologie und Deutsches Zentrum für Lungenforschung (DZL), Hannover
| | - S Schmidt
- Ernst-Moritz-Arndt Universität Greifswald, Zentrum für Kinder- und Jugendmedizin; Mukoviszidose Zentrum Mecklenburg/Vorpommern, Greifswald
| | - L Sedlacek
- Medizinische Hochschule Hannover, Institut für Medizinische Mikrobiologie und Krankenhaushygiene, Hannover
| | - H Sitter
- Philipps-Universität Marburg, Institut für theoretische Medizin, Marburg
| | - C Smaczny
- Klinikum der Johann Wolfgang Goethe-Universität Frankfurt am Main, Zentrum der Inneren Medizin, Frankfurt, Deutschland
| | - B Tümmler
- Medizinische Hochschule Hannover, Klinische Forschergruppe OE 6710, Klinik für Pädiatrische Pneumologie und Neonatologie
| | - R Vonberg
- Medizinische Hochschule Hannover, Institut für Medizinische Mikrobiologie und Krankenhaushygiene, Hannover
| | - M O Wielpütz
- Diagnostische und Interventionelle Radiologie Universitätsklinikum Heidelberg, Heidelberg
| | - H Wilkens
- Universitätsklinikum des Saarlandes, Medizinische Klinik V, Pneumologie, Allergologie und Beatmungsmedizin, Homburg
| | - B Wollschläger
- Martin-Luther-Universität Halle, Universitätsklinik und Poliklinik für Innere Medizin I/Pneumologie, Halle
| | - J Zerlik
- Altonaer Kinderkrankenhaus gGmbH, Abteilung Physiotherapie, Hamburg
| | | | | |
Collapse
|
9
|
Smaczny C, Eickmeier O, Hügel C, Rohde G. Vorbeugung einer MRSA-Übertragung von CF-Mutter auf ihr ebenfalls an CF erkranktes Kind. Pneumologie 2018. [DOI: 10.1055/s-0037-1619207] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- C Smaczny
- Pneumologie, J. W. Goethe-Universitätsklinik Frankfurt a.M
| | - O Eickmeier
- Kinderklinik, J. W. Goethe-Universitätsklinik Frankfurt a.M
| | - C Hügel
- Pneumologie, J. W. Goethe-Universitätsklinik Frankfurt a.M
| | - G Rohde
- Pneumologie, J. W. Goethe-Universitätsklinik Frankfurt a.M
| |
Collapse
|
10
|
Pietzner J, Merscher BM, Baer PC, Duecker RP, Eickmeier O, Fußbroich D, Bader P, Del Turco D, Henschler R, Zielen S, Schubert R. Low-dose irradiation prior to bone marrow transplantation results in ATM activation and increased lethality in Atm-deficient mice. Bone Marrow Transplant 2016; 51:619. [PMID: 27050750 DOI: 10.1038/bmt.2016.22] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
11
|
Ludwig M, Eickmeier O, Smaczny C, Schreiner F, Dubois W, NGampolo D, Schubert R, Zielen S, Ganschow R, Schmitt-Grohé S. Connexin 37 and Connexin 43 genotypes in correlation to cytokines in induced sputum and blood in cystic fibrosis (CF). Mol Cell Pediatr 2014. [PMCID: PMC4715121 DOI: 10.1186/2194-7791-1-s1-a11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
|
12
|
Eickmeier O, Seki H, Haworth O, Hilberath JN, Gao F, Uddin M, Croze RH, Carlo T, Pfeffer MA, Levy BD. Aspirin-triggered resolvin D1 reduces mucosal inflammation and promotes resolution in a murine model of acute lung injury. Mucosal Immunol 2013; 6:256-66. [PMID: 22785226 PMCID: PMC3511650 DOI: 10.1038/mi.2012.66] [Citation(s) in RCA: 148] [Impact Index Per Article: 13.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Acute lung injury (ALI) is a severe illness with excess mortality and no specific therapy. Protective actions were recently uncovered for docosahexaenoic acid-derived mediators, including D-series resolvins. Here, we used a murine self-limited model of hydrochloric acid-induced ALI to determine the effects of aspirin-triggered resolvin D1 (AT-RvD1; 7S,8R,17R-trihydroxy-4Z,9E,11E,13Z,15E,19Z-docosahexaenoic acid) on mucosal injury. RvD1 and its receptor ALX/FPR2 were identified in murine lung after ALI. AT-RvD1 (~0.5-5 μg kg(-1)) decreased peak inflammation, including bronchoalveolar lavage fluid (BALF) neutrophils by ~75%. Animals treated with AT-RvD1 had improved epithelial and endothelial barrier integrity and decreased airway resistance concomitant with increased BALF epinephrine levels. AT-RvD1 inhibited neutrophil-platelet heterotypic interactions by downregulating both P-selectin and its ligand CD24. AT-RvD1 also significantly decreased levels of BALF pro-inflammatory cytokines, including interleukin (IL)-1β, IL-6, Kupffer cells, and tumor necrosis factor-α, and decreased nuclear factor-κB-phosphorylated p65 nuclear translocation. Taken together, these findings indicate that AT-RvD1 displays potent mucosal protection and promotes catabasis after ALI.
Collapse
Affiliation(s)
- O. Eickmeier
- Pulmonary and Critical Care Medicine, Department of Internal Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA
| | - H. Seki
- Pulmonary and Critical Care Medicine, Department of Internal Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA
| | - O. Haworth
- Pulmonary and Critical Care Medicine, Department of Internal Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA
| | - JN. Hilberath
- Pulmonary and Critical Care Medicine, Department of Internal Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA
| | - F. Gao
- Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA
| | - M. Uddin
- Pulmonary and Critical Care Medicine, Department of Internal Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA
| | - RH. Croze
- Pulmonary and Critical Care Medicine, Department of Internal Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA
| | - T. Carlo
- Pulmonary and Critical Care Medicine, Department of Internal Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA
| | - MA. Pfeffer
- Pulmonary and Critical Care Medicine, Department of Internal Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA
| | - BD. Levy
- Pulmonary and Critical Care Medicine, Department of Internal Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA,Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA,Corresponding author: Bruce D. Levy, MD, Pulmonary and Critical Care Medicine, Department of Internal Medicine, Brigham and Women’s Hospital and Harvard Medical School, Harvard Institutes of Medicine Bldg, 77 Avenue Louis Pasteur (HIM 855), Boston, MA 02115, USA, Phone: 617-525-5407, Fax: 617-525-5413,
| |
Collapse
|
13
|
Rosewich M, Kheiri T, Eickmeier O, Zissler U, Schubert R, Zielen S. Bronchiolitis obliterans bei Kindern und Jugendlichen. Pneumologie 2013. [DOI: 10.1055/s-0033-1334766] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
14
|
Rosewich M, Eickmeier O, Zissler U, Serve F, Leutz P, Schubert R, Zielen S. 162 Airway inflammation in mild cystic fibrosis patients with small airway disease. J Cyst Fibros 2012. [DOI: 10.1016/s1569-1993(12)60332-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
15
|
Serve F, Eickmeier O, Rosewich M, Leutz P, Zissler U, Zielen S, Kirkamm R. 245 Fatty acids and bronchial inflammation in mild cystic fibrosis. J Cyst Fibros 2012. [DOI: 10.1016/s1569-1993(12)60414-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
16
|
Eickmeier O, Zissler U, Unger F, Rosewich M, Schubert R, Zielen S. 229* Clinical relevance of Aspergillus in cystic fibrosis patients sensitized to Aspergillus. J Cyst Fibros 2011. [DOI: 10.1016/s1569-1993(11)60245-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
17
|
Abstract
Uncontrolled inflammation of the lung contributes to the major medical and economic burden on healthcare, and the need for therapeutics to dampen pathological inflammation is largely unmet. Recently, a new genus of anti-inflammatory/ pro-resolving lipid mediators has been identified: Lipoxins, resolvins, protectins and maresins. These compounds are enzymatically derived from the polyunsaturated fatty acids (PUFAs) arachidonic acid (AA), docosahexaenoic acid (DHA), and eicosapentaenoic acid (EPA) that have long been known to have beneficial health properties. These mediators have potent anti-inflammatory effects IN VITRO and IN VIVO in murine models of lung inflammation. Therefore, this group of compounds carries considerable therapeutic potential for the treatment of many inflammatory lung diseases including asthma, cystic fibrosis and acute lung injury.
Collapse
Affiliation(s)
- O Eickmeier
- Zentrum für Kinder- und Jugendmedizin, Allergologie, Pneumologie und Mukoviszidose, Klinikum der Johann Wolfgang Goethe- Universität Frankfurt a.M.
| | | | | | | |
Collapse
|
18
|
Rosewich M, Schulze J, Eickmeier O, Telles T, Rose MA, Schubert R, Zielen S. Tolerance induction after specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A in children. Clin Exp Immunol 2010; 160:403-10. [PMID: 20345983 DOI: 10.1111/j.1365-2249.2010.04106.x] [Citation(s) in RCA: 50] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
Specific immunotherapy (SIT) is a well-established and clinically effective treatment for allergic diseases. A pollen allergoid formulated with the T helper type 1 (Th1)-inducing adjuvant monophosphoryl lipid A (MPL) facilitates short-term SIT. Little is known about mechanisms of tolerance induction in this setting. In a prospective study, 34 patients allergic to grass pollen (25 male, nine female, median age 10.2 years) received a total of 44 SIT courses (20 in the first, 24 in the second) with MPL-adjuvanted pollen allergoids. Immunogenicity was measured by levels of specific immunoglobulin G (IgG(grass)) and IgG4(grass) by antibody blocking properties on basophil activation, and by induction of CD4(+), CD25(+) and forkhead box P3 (FoxP3(+)) regulatory T cells (T(reg)). Specific IgG and IgG4 levels increased only slightly in the first year of SIT. In the second year these changes reached significance (P < 0.0001). In keeping with these findings, we were able to show an increase of T(reg) cells and a decreased release of leukotrienes after the second year of treatment. In the first year of treatment we found little evidence for immunological changes. A significant antibody induction was seen only after the second course of SIT. Short-course immunotherapy with pollen allergoids formulated with the Th1-inducing adjuvant MPL needs at least two courses to establish tolerance.
Collapse
Affiliation(s)
- M Rosewich
- Paediatric Pulmonology and Allergology, Goethe University, Frankfurt/Main, Germany.
| | | | | | | | | | | | | |
Collapse
|
19
|
Schubert R, Eickmeier O, Garn H, Baer PC, Mueller T, Schulze J, Rose MA, Rosewich M, Renz H, Zielen S. Safety and immunogenicity of a cluster specific immunotherapy in children with bronchial asthma and mite allergy. Int Arch Allergy Immunol 2008; 148:251-60. [PMID: 18849616 DOI: 10.1159/000161585] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2008] [Accepted: 06/10/2008] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND Cluster specific immunotherapy (SIT) is a modern form of allergen immunotherapy allowing safe administration of high allergen doses in a short time interval compared to classic SIT. In the current study, we investigated the safety profile and immunological effect of cluster SIT in children with allergic asthma due to house dust mite allergy. METHODS A total of 34 children (6-18 years) with allergic asthma were assigned to cluster (n = 22) or classic SIT (n = 12). To achieve a maintenance dose of allergen extract, cluster patients received 14 injections of house dust mite allergen within 6 weeks, whereas the classic SIT group received 14 injections within 14 weeks. Safety was monitored by recording adverse events. Immunogenicity was measured by specific IgG(Mite) and IgG4(Mite), by antibody-blocking properties on basophil activation, and by the T cell subset transcription factors Foxp3, T-bet, and GATA-3. RESULTS There were no significant differences in local and systemic side effects between the two groups. In the cluster group, serum levels of specific IgG(Mite) (p < 0.001) and specific IgG4(Mite) (p < 0.001) significantly increased after 8 weeks, while it took 12 weeks in the classic SIT group. These data were confirmed by blocking CD63 expression as well as release of cysteinyl leukotrienes after in vitro basophil stimulation. No differences in transcription factor expression were found in the two groups. CONCLUSION Cluster SIT is safe in children. Additionally, our data demonstrated an even more rapid induction of specific immune tolerance. Cluster SIT is an attractive alternative to conventional up-dosing schedules with fewer consultations for the patients.
Collapse
Affiliation(s)
- R Schubert
- Paediatric Pulmonology and Allergology, Department of Internal Medicine III, J.W. Goethe University, Frankfurt am Main, Germany.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Abstract
The present study investigated whether single-dose oral leukotriene receptor antagonists as add-on therapy to short-acting beta-agonists, immediately after allergen challenge, block the late-phase airway response. In total, 35 mild asthmatics (mean age 24 yrs, 19 males) sensitised for house dust mites underwent two courses of bronchial allergen challenge. After the early allergic response (EAR), subjects received salbutamol once and were randomly assigned to either 10 mg of montelukast or placebo (double-blind crossover). To identify a late allergic response, forced expiratory volume in one second (FEV(1)) was monitored over the following 8 h. Baseline exhaled nitric oxide (NO) was determined ahead of each allergen challenge. Baseline NO levels differed significantly depending on the reaction to allergen challenge. In total, 12 subjects showed no significant response, 11 only showed an EAR, and 12 had a dual response and underwent further analysis. The area under the FEV(1) time-response curve 3-8 h after bronchial allergen challenge was -0.77+/-1.68 from the pre-challenge values on montelukast compared with -2.47+/-1.32 on placebo. The baseline exhaled NO fraction of subjects without an EAR was significantly lower than of those presenting a dual response. The results of the present study demonstrate that single-dose leukotriene receptor antagonists given orally right after the early allergic response can significantly inhibit the late allergic response after bronchial allergen challenge.
Collapse
Affiliation(s)
- M Rosewich
- Dept of Paediatrics, Frankfurt University, Frankfurt, Germany.
| | | | | | | | | | | |
Collapse
|
21
|
Eickmeier O, Rosewich M, Stieglitz F, Kitz R, Rose M, Zielen S. Variabilität des exhalierten NO (eNO) bei Patienten mit allergischem Asthma bronchiale (GINA I). Pneumologie 2004. [DOI: 10.1055/s-2004-819549] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|